The prefilled, patient-ready-to-use system is said to support delivery of high-viscosity biologics of up to 50 centipoise.

Becton Dickinson (BDX) announced the first pharma-sponsored combination product clinical trial using the BD Libertas Wearable Injector for ...

Franklin Lakes, New Jersey Thursday, July 24, 2025, 14:00 Hrs [IST] ...

Shares of Becton Dickinson and Co. dropped in early Monday trading after the medical-products company announced a deal to ...

Milford-based biotech company Waters Corp. will merge with Becton, Dickinson and Co.’s biosciences an diagnostic solutions ...

Lab equipment maker Waters Corp on Monday said it will buy a bioscience and diagnostics unit spun off from medtech provider ...

Waters said it reached a deal to buy the Biosciences & Diagnostic Solutions business of Becton Dickinson for around $17.5 ...

Becton Dickinson plans to pay $4.2 billion for Edwards Lifesciences’ critical care business, which sells technology that monitors the heart conditions of critically ill patients. Edwards had ...

Becton Dickinson (BDX) recently announced the initiation of a pharma-sponsored clinical trial featuring their BD Libertas Wearable Injector, alongside an affirmed quarterly dividend and leadership ...

Becton, Dickinson's divestment enhances focus, reduces leverage, funds buybacks, and unlocks value. Read more about the M&A ...

Becton Dickinson (BDX) announced that the BD Onclarity HPV Assay has officially been added to the American Society for Colposcopy and Cervical Pathology, or ASCCP, enduring risk-based management ...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announces the first pharma-sponsored combination product clinical trial using the BD Libertas™ Wearable ...